Oncology roundtable meeting

1. Panelist Bios:
Glen Doucet
Mr. Glen Doucet has been Vice President of Advocacy at Canadian Pharmacists
Association (CPHA) since October 27, 2014. Mr. Doucet is a government relations and
public affairs expert with more than 23 years of experience working in political,
governmental and non-governmental organizations. Prior to his most recent role as
Executive Director for the Fur Institute of Canada, he spent four years as the Vice
President, Government Relations & Public Affairs with the Canadian Diabetes
Association and 10 years with the Government Relations group at the Canadian
Medical Association.
Louise Binder
Louise Binder is a lawyer and health advocate who has been involved in informing the
development of health policy and systemic treatment access practices from a patient
perspective for more than 20 years. She started her work in this area in the HIV
community in the early 1990s after her own diagnosis and before effective treatments
were available for HIV. She co-founded the Canadian Treatment Action Council (CTAC)
in 1996, which successfully ensured access to treatments and quality care for people
living with HIV by working with the federal and provincial governments and other
relevant stakeholders to enhance drug review and approval systems, pricing policies
and access to liver transplants for this community. She wrote a paper on universal drug
coverage a decade ago while chair of CTAC. She had a special interest in women's
issues, chairing the Ontario women's organization Voice of Positive Women for more
than a decade, and has been involved in these issues internationally as well. Two years
ago, Louise began similar work in the cancer area and is presently health policy
consultant for the Canadian Cancer Survivor Network. She has been recognized by
many organizations for her work, including receiving an Honorary Doctorate of Laws
from her alma mater, Queen's Law School; the Order of Ontario from the Province of
Ontario; and two Queen Elizabeth II medals.
Marc-André Gagnon
Associate Professor with Carleton University’s School of Public Policy and
Administration. He holds a PhD in Political Science from York University and a Master’s
of Advanced Study in Economics from Paris-1 Sorbonne and École Normale Supérieure
de Fontenay/St-Cloud. He did his post-doctoral training with the Centre for Intellectual
Property Policy at McGill University’s Faculty of Law, and with the Edmond J. Safra
Center for Ethics at Harvard University. His current research focuses mainly on the
political economy of the pharmaceutical sector. He analyzes institutional corruption in
the pharmaceutical sector, regulatory capture of public institutions, innovation policies
and intellectual property in the knowledge-based economy, as well as comparative
regimes of health insurance and Pharmacare. He is currently Fellow with the WHO
Collaborating Centre for Governance, Accountability and Transparency in the
Pharmaceutical Sector, and researcher with the Rational Therapeutics and Medication
Policy research group.

2. Don Husereau
Don Husereau is an Adjunct Professor of Medicine at The University of Ottawa, Senior
Associate with the Institute of Health Economics, and Senior Scientist at the University
for Health Sciences, Medical Informatics and Technology in Hall in Tirol, Austria. Don’s
current research focuses on appropriate and innovative approaches to the use of
evidence and economics to inform health policy based on sound principles of social
justice, epistemology, and judgment and decision-making. He is currently Chair of an
International Task Force that has developed consolidated health economic evaluation
reporting standards (CHEERS) that is now endorsed by leading biomedical and health
policy journals. Don is currently an Editorial Advisor for the biomedical journals, Value in
Health and BMC Medicine. He also serves on the pan-Canadian Oncology Drug Review
(pCODR) Expert Review Committee (pERC) and Ontario Committee to Evaluate Drugs.
Don received both his BSc and MSc from the University of Alberta's faculty of Pharmacy
and Pharmaceutical Sciences.
W. Neil Palmer
President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing
and reimbursement consultancy founded) in 1996. At PDCI, he leads a senior team of
market access professionals with pricing & reimbursement engagements focusing
primarily on the Canadian market. Neil is also Adjunct Assistant Professor at the
University of Southern California School of Pharmacy graduate program in Health Care
Decision Analysis where he lectures on health technology assessment, pricing and
market access from a global perspective. Neil served as global vice president for pricing
and reimbursement with RTI Health Solutions of RTP North Carolina from 2006 – 2009.
He previously worked with the Canadian Patented Medicine Prices Review Board
(PMPRB), the Health Division of Statistics Canada and the research group of the
Kellogg Centre for Advanced Studies in Primary Care in Montreal. A graduate of the
University of Western Ontario, Neil has written extensively on pharmaceutical pricing
and reimbursement issues and is a frequent speaker at conferences in North America
and Europe.